NVSE.F Stock Overview
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Novartis AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF96.39 |
52 Week High | CHF109.00 |
52 Week Low | CHF88.50 |
Beta | 0.46 |
1 Month Change | -7.18% |
3 Month Change | -1.94% |
1 Year Change | 16.50% |
3 Year Change | 13.60% |
5 Year Change | 0.28% |
Change since IPO | 139.48% |
Recent News & Updates
Recent updates
Shareholder Returns
NVSE.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -3.6% | -0.06% | 2.1% |
1Y | 16.5% | 23.6% | 30.4% |
Return vs Industry: NVSE.F underperformed the US Pharmaceuticals industry which returned 23.6% over the past year.
Return vs Market: NVSE.F underperformed the US Market which returned 30.4% over the past year.
Price Volatility
NVSE.F volatility | |
---|---|
NVSE.F Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 9.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVSE.F has not had significant price volatility in the past 3 months.
Volatility Over Time: NVSE.F's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 76,057 | Vas Narasimhan | https://www.novartis.com |
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG Fundamentals Summary
NVSE.F fundamental statistics | |
---|---|
Market cap | US$210.96b |
Earnings (TTM) | US$8.57b |
Revenue (TTM) | US$46.66b |
24.6x
P/E Ratio4.5x
P/S RatioIs NVSE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NVSE.F income statement (TTM) | |
---|---|
Revenue | US$46.66b |
Cost of Revenue | US$12.02b |
Gross Profit | US$34.64b |
Other Expenses | US$26.07b |
Earnings | US$8.57b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 23, 2024
Earnings per share (EPS) | 3.91 |
Gross Margin | 74.24% |
Net Profit Margin | 18.36% |
Debt/Equity Ratio | 52.6% |
How did NVSE.F perform over the long term?
See historical performance and comparison